|
1
|
Li J, Yang Z, Li Y, Xia J, Li D, Li H, Ren
M, Liao Y, Yu S, Chen Y, et al: Cell apoptosis, autophagy and
necroptosis in osteosarcoma treatment. Oncotarget. 7:44763–44778.
2016.PubMed/NCBI
|
|
2
|
Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH
and Wang WJ: MicroRNAs in osteosarcoma. Clin Chim Acta. 444:9–17.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou RT, He M, Yu Z, Liang Y, Nie Y, Tai S
and Teng CB: Baicalein inhibits pancreatic cancer cell
proliferation and invasion via suppression of NEDD9 expression and
its downstream Akt and ERK signaling pathways. Oncotarget.
8:56351–56363. 2017.PubMed/NCBI
|
|
4
|
Liu X and Liu S, Chen J, He L, Meng X and
Liu S: Baicalein suppresses the proliferation of acute
T-lymphoblastic leukemia Jurkat cells by inhibiting the
Wnt/β-catenin signaling. Ann Hematol. 95:1787–1793. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei N, Wei Y, Li B and Pang L: Baicalein
promotes neuronal and behavioral recovery after intracerebral
hemorrhage via suppressing apoptosis, Oxidative stress and
neuroinflammation. Neurochem Res. 42:1345–1353. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ye H, Zhang Y, Wang Y, Xia J, Mao X and Yu
X: The restraining effect of baicalein and U0126 on human cervical
cancer cell line HeLa. Mol Med Rep. 16:957–963. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chai Y, Xu J and Yan B: The
anti-metastatic effect of baicalein on colorectal cancer. Oncol
Rep. 37:2317–2323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi EO, Park C, Hwang HJ, Hong SH, Kim
GY, Cho EJ, Kim WJ and Choi YH: Baicalein induces apoptosis via
ROS-dependent activation of caspases in human bladder cancer 5637
cells. Int J Oncol. 49:1009–1018. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma X, Yan W, Dai Z, Gao X, Ma Y, Xu Q,
Jiang J and Zhang S: Baicalein suppresses metastasis of breast
cancer cells by inhibiting EMT via downregulation of SATB1 and
Wnt/β-catenin pathway. Drug Des Devel Ther. 10:1419–1441. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Palmini G, Marini F and Brandi ML: What is
new in the miRNA world regarding osteosarcoma and chondrosarcoma?
Molecules. 22:pii: E417. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zoni E and van der Pluijm G: The role of
microRNAs in bone metastasis. J Bone Oncol. 5:104–108. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao LL, Xie JW, Lin Y, Zheng CH, Li P,
Wang JB, Lin JX, Lu J, Chen QY and Huang CM: miR-183 inhibits
invasion of gastric cancer by targeting Ezrin. Int J Clin Exp
Pathol. 7:5582–5594. 2014.PubMed/NCBI
|
|
13
|
Li M, Feng YM and Fang SQ: Overexpression
of ezrin and galectin-3 as predictors of poor prognosis of cervical
cancer. Braz J Med Biol Res. 50:e53562017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kong J, Li Y, Liu S, Jin H, Shang Y, Quan
C, Li Y and Lin Z: High expression of ezrin predicts poor prognosis
in uterine cervical cancer. BMC Cancer. 13:5202013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang
X and Wang L: Down-regulation of miR-183 promotes migration and
invasion of osteosarcoma by targeting Ezrin. Am J Pathol.
180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Zuo J, Lei M, Wu S, Zang X and
Zhang C: Ezrin promotes invasion and migration of the MG63
osteosarcoma cell. Chin Med J (Engl). 127:1954–1959.
2014.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kushlinskii NE, Fridman MV and Braga EA:
Molecular mechanisms and microRNAs in osteosarcoma pathogenesis.
Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao Y, Snyder SA, Smith JN and Chen YC:
Anticancer properties of baicalein: A review. Med Chem Res.
25:1515–1523. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dinda B, Dinda S, DasSharma S, Banik R,
Chakraborty A and Dinda M: Therapeutic potentials of baicalin and
its aglycone, baicalein against inflammatory disorders. Eur J Med
Chem. 131:68–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chung H, Choi HS, Seo EK, Kang DH and Oh
ES: Baicalin and baicalein inhibit transforming growth
factor-β1-mediated epithelial-mesenchymal transition in human
breast epithelial cells. Biochem Biophys Res Commun. 458:707–713.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dai G, Zheng D, Wang Q, Yang J, Liu G,
Song Q, Sun X, Tao C, Hu Q, Gao T, et al: Baicalein inhibits
progression of osteosarcoma cells through inactivation of the
Wnt/β-catenin signaling pathway. Oncotarget. 8:86098–86116. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He N and Zhang Z: Baicalein suppresses the
viability of MG-63 osteosarcoma cells through inhibiting c-MYC
expression via Wnt signaling pathway. Mol Cell Biochem.
405:187–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ye F, Wang H, Zhang L, Zou Y, Han H and
Huang J: Baicalein induces human osteosarcoma cell line MG-63
apoptosis via ROS-induced BNIP3 expression. Tumour Biol.
36:4731–4740. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pal MK, Jaiswar SP, Dwivedi VN, Tripathi
AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising
potential biomarker for diagnosis and prognosis of ovarian cancer.
Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI
|
|
27
|
Taylor MA and Schiemann WP: Therapeutic
opportunities for targeting microRNAs in cancer. Mol Cell Ther.
2:1–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nugent M: microRNA and bone cancer. Adv
Exp Med Biol. 889:201–230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang
Q, Cheng P, Tang ZH and Huang F: Meta-analysis of microRNA-183
family expression in human cancer studies comparing cancer tissues
with noncancerous tissues. Gene. 527:26–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mu Y, Zhang H, Che L and Li K: Clinical
significance of microRNA-183/Ezrin axis in judging the prognosis of
patients with osteosarcoma. Med Oncol. 31:8212014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X
and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via
downregulation of the expression of Ezrin in F5M2 cells. Int J Mol
Med. 30:1013–1020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abdou AG, Kandil M, Asaad NY, Dawoud MM,
Shahin AA and Eldayem Abd AF: The prognostic role of Ezrin and
HER2/neu expression in osteosarcoma. Appl Immunohistochem Mol
Morphol. 24:355–363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao DH, Zhu J, Wang WB, Dong F, Zhang Q,
Fan HW, Zhang JZ and Wang YM: Correlations of ezrin expression with
pathological characteristics and prognosis of osteosarcoma: A
meta-analysis. ScientificWorldJournal. 2014:8375432014. View Article : Google Scholar : PubMed/NCBI
|
